{
    "xml": "<topic id=\"PHP80911\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/convulex\" basename=\"convulex\" title=\"Convulex\">\n<title>Convulex<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP81005\" outputclass=\"indicationsAndDose\" rev=\"1.31\" parent=\"/clinical-medicinal-product-information/convulex\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Epilepsy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>Totally daily dose to be given in 2&#8211;4 divided doses (consult product literature).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Totally daily dose to be given in 2&#8211;4 divided doses (consult product literature).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>\n<i>Convulex</i>\n<tm tmtype=\"reg\"/> has a 1:1 dose relationship with products containing sodium valproate, but nevertheless care is needed if switching or making changes.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP81031\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/clinical-medicinal-product-information/convulex\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Patients being treated for epilepsy may need to be maintained on a specific manufacturer's branded or generic oral valproic acid product.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP81025\" outputclass=\"patientAndCarerAdvice\" rev=\"1.9\" parent=\"/clinical-medicinal-product-information/convulex\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundDrivingAndOtherTasks\">\n<title>Driving and skilled tasks</title>\n<sectiondiv>\n<p>Patients with epilepsy may drive a motor vehicle (but not a large goods or passenger carrying vehicle) provided that they have been seizure-free for one year or, if subject to attacks only while asleep, have established a 3-year period of asleep attacks without awake attacks. Those affected by drowsiness should not drive or operate machinery.</p>\n<p>Guidance issued by the Drivers Medical Unit of the Driver and Vehicle Licensing Agency (DVLA) recommends that patients should be advised not to drive during medication changes or withdrawal of antiepileptic drugs, and for 6 months afterwards.</p>\n<p>Patients who have had a first or single epileptic seizure must not drive for 6 months (5 years in the case of large goods or passenger carrying vehicles) after the event; driving may then be resumed, provided the patient has been assessed by a specialist as fit to drive because no abnormality was detected on investigation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP80911",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/convulex",
    "basename": "convulex",
    "title": "Convulex",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Epilepsy",
                        "html": "Epilepsy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "Totally daily dose to be given in 2&#8211;4 divided doses (consult product literature).",
                        "html": "<p>Totally daily dose to be given in 2&#8211;4 divided doses (consult product literature).</p>"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Totally daily dose to be given in 2&#8211;4 divided doses (consult product literature).",
                        "html": "<p>Totally daily dose to be given in 2&#8211;4 divided doses (consult product literature).</p>"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "Convulex has a 1:1 dose relationship with products containing sodium valproate, but nevertheless care is needed if switching or making changes.",
                "html": "<p>\n<i>Convulex</i>\n<tm tmtype=\"reg\"/> has a 1:1 dose relationship with products containing sodium valproate, but nevertheless care is needed if switching or making changes.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Patients being treated for epilepsy may need to be maintained on a specific manufacturer's branded or generic oral valproic acid product.",
                "html": "<p>Patients being treated for epilepsy may need to be maintained on a specific manufacturer's branded or generic oral valproic acid product.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundDrivingAndOtherTasks": [
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "textContent": "Patients with epilepsy may drive a motor vehicle (but not a large goods or passenger carrying vehicle) provided that they have been seizure-free for one year or, if subject to attacks only while asleep, have established a 3-year period of asleep attacks without awake attacks. Those affected by drowsiness should not drive or operate machinery.\n\nGuidance issued by the Drivers Medical Unit of the Driver and Vehicle Licensing Agency (DVLA) recommends that patients should be advised not to drive during medication changes or withdrawal of antiepileptic drugs, and for 6 months afterwards.\n\nPatients who have had a first or single epileptic seizure must not drive for 6 months (5 years in the case of large goods or passenger carrying vehicles) after the event; driving may then be resumed, provided the patient has been assessed by a specialist as fit to drive because no abnormality was detected on investigation.",
                "html": "<p>Patients with epilepsy may drive a motor vehicle (but not a large goods or passenger carrying vehicle) provided that they have been seizure-free for one year or, if subject to attacks only while asleep, have established a 3-year period of asleep attacks without awake attacks. Those affected by drowsiness should not drive or operate machinery.</p><p>Guidance issued by the Drivers Medical Unit of the Driver and Vehicle Licensing Agency (DVLA) recommends that patients should be advised not to drive during medication changes or withdrawal of antiepileptic drugs, and for 6 months afterwards.</p><p>Patients who have had a first or single epileptic seizure must not drive for 6 months (5 years in the case of large goods or passenger carrying vehicles) after the event; driving may then be resumed, provided the patient has been assessed by a specialist as fit to drive because no abnormality was detected on investigation.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}